GMR
The Original

MOLECULAR MECHANISMS OF MICROBIAL RESISTANCE: IMPLICATIONS FOR BIOTECHNOLOGY AND DRUG DEVELOPMENT

[1*]Dr. Himanshu Narula,[2] Zohra Muslumova, [3]Rekha Anantharaman,[4] Dr. Biju Sidharthan, [5] D. Munirajasekhar

[1*]Associate Professor, Microbiology, Government Medical College, Haridwar, Email Id: narula02himanshu@gmail.com, Orcid Id: 0000-0007-1658-797X
[2] Associate Prof., Institute of Physics Public Legal Entity, Ministry of Science and Education of the Republic of Azerbaijan
Email Id: zohre.biologist@gmail.com, Orcid Id: 0009-0007-8131-9230
[3]Microbial Research Lab, Department of Obstetrics and Gyanecology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai 602105, Tamil Nadu, India, Email Id: microrekha@gmail.com, Orcid Id: 0009-0009-9956-8803
[4]Scientist, Plant Breeding and Genetics, Kerala Agricultural University, Thrissur, Kerala-680656, India
Email Id: biju.s@kau.in, Orcid Id: 0009-0008-9775-7650
[5]Professor, Department of Chemistry, Synthetic & Medicinal Chemistry Research Lab, Siddharth Institute of Engineering & Technology (Autonomous), Puttur, Andhra Pradesh- 517583, India, Email Id: chemmuni@gmail.com, Orcid Id: 0000-0002-2042-9424

ABSTRACT
Antimicrobial resistance (AMR) has emerged as a significant biological and therapeutic issue, compromising the efficacy of currently available antibiotics and enhancing the frequency of infections that are challenging to treat in the world. This paper explores the molecular understanding of microbial resistance and its application to biotechnology and drug development with an experimental dataset of antimicrobial resistance data at the level of gene-level resistance determinants, resistance-class indicators, and genomic variables. Quantitative analytical design was used to analyze the distribution of resistance genes, categorize them into functional molecular groups and examine co-occurrence relationships that are linked to multidrug resistance. The analysis showed that the burden of resistance against all the microbial isolates was consistently high as indicated by the high number of antimicrobial resistance genes and resistance classes that were identified per isolate. Classification using mechanism revealed that efflux-mediated resistance was the pathway, enzymatic degradation, membrane-associated resistance, and target modification or protection. The concomitant presence of several resistance determinants also showed that the organization of resistance is through combined molecular mechanisms as opposed to single gene action. These trends suggest that there are stable multidrug resistance structures in the isolates investigated. This paper has indicated the importance of mechanism-based resistance analysis in biotechnology especially in resistance profiling, genomic interpretation and therapeutic targeting. In terms of drug development, the results highlight the need to focus on the main mechanisms like efflux systems or enzymes that inactivate drugs to enhance antimicrobial efficacy.

KEYWORDS: antimicrobial resistance, molecular mechanisms, efflux-mediated resistance, multidrug resistance, drug development

INTRODUCTION
Antimicrobial resistance (AMR) has become one of the greatest health hazards in the world, diminishing the efficacy of antimicrobial treatment and increasing the problems in treating infectious diseases in various clinical environments. AMR is a significant biomedical and public health challenge, as the current development of resistant microorganisms has risen morbidity, mortality, healthcare spending, and the burden on health systems, overall (Naghavi et al., 2024). Besides its clinical implications, AMR also poses significant scientific and technological challenges due to its ability to undermine the effectiveness of the available antibiotics in the long term and reduce the therapeutic potential in the future to control infections (Irfan et al., 2022).
Microbial resistance at the molecular level is instigated by a number of interacting biological processes which enable the pathogens to endure when subjected to antimicrobials. Such mechanisms often involve enzymatic breakdown of antibiotics, active efflux of drugs, target modification or shielding and changes in membrane permeability that diminish the uptake of antibiotics. This resistance can be inherent to the microbial species or it can be acquired due to mutation and horizontal gene transfer, so the microorganisms can quickly adapt to the selective antimicrobial pressure (Oliveira et al., 2024). With the accumulation of these mechanisms in the same organism, they tend to produce multidrug-resistant phenotypes that are becoming more challenging to control both in the clinical and environmental context.
Enzymatic inactivation is one of the most important mechanisms contributing to the antibiotic failure in clinical practice. Enzymes that inactivate drugs, most notably beta-lactamases, are able to digest antibiotics before they can

reach their targets on cells and, therefore, make treatment ineffective (Christaki et al., 2020). Another key resistance pathway is the efflux pumps which actively extracellularly expel antimicrobial agents and reduces cellular levels of drugs. Likewise, the mechanisms of changing the target modify the sites where the antibiotics bind to the molecules, and the alterations associated with the membrane limit the access of the drugs, as well as the decreased reluctance (Sartori et al., 2026). The presence of these mechanisms in one isolate usually leads to broad spectrum resistance and has a significant role in the survival of resistant populations of microbes.

These implications of AMR on biotechnology are significant. Innovations in microbial profiling, resistance mapping, and molecular characterization have enhanced the capacity to identify and comprehend resistance determinants in more detail on a gene level. This information could be used in strengthening surveillance of resistant to improve diagnostic accuracy and assist the creation of biotechnology-based solutions to monitor and control resistant pathogens . A comprehensive mechanistic explanation of AMR can thus play the role of connecting basic microbiological studies with the utilization of technology in the healthcare and microbial biotechnology field (Solanki & Kumar Das, 2024).

AMR is also vital when it comes to drug development. The fact that even new antibiotics are rapidly being defeated by resistance, is indicative of the fact that therapeutic innovation needs to be backed by a very good comprehension of the molecular pathways that compromise the effect of drugs (Schardong et al., 2026). This has led to more concern about the solutions like enzyme inhibitors, efflux pump blockers, rational drug modification, and combination therapy to overcome the existing mechanisms of resistance (Konaklieva, 2019). In medicinal and synthetic chemistry terms, direct antimicrobial potency is not the only way in which antimicrobial agents may be successful in the future, but also by their ability to circumvent or inhibit microbial resistance determinants.

On a larger scale, ecological and evolutionary mechanisms are involved in maintaining AMR sustainability and enhancing the proliferation and dissemination of resistance genes in microbial groups (Hernández-Navarro et al., 2024). International studies have demonstrated that the cost of bacterial AMR is already high and is likely to grow even bigger unless effective counteractions to it are developed (Naghavi et al., 2024). All these realities underscore the importance of in-depth investigations that are aimed at specifically studying the molecular architecture of resistance and the biological processes that contribute to expression of resistance in microbe isolates (Ho et al., 2025).

Here, the current paper examines the molecular pathways of antimicrobial resistance through a curated dataset of antimicrobial resistance that includes gene-level determinants of resistance, indicators of resistance-class and genomic variables. The aim of the study is to examine the distribution of the resistance genes, classify them into major molecular resistance groups and patterns of co-occurrence that can possibly lead to multidrug resistance behavior. It also translates these results and applies them to biotechnology and drug development by associating the prevalent resistance mechanisms to target antibiotic classes, and possible interventions. With this method, the research seeks to give a biological and translationally relevant mechanism-based and systematic knowledge of microbial resistance.

1.To analyze the distribution of antimicrobial resistance genes, resistance classes, and genomic variables across microbial isolates.

2.To assess the major molecular mechanisms of resistance by classifying resistance determinants into functional categories.

3.To evaluate the implications of identified resistance mechanisms for biotechnology and drug development strategies.

2. METHODOLOGY

2.1 Research Design

The current research used a quantitative analytical research design to explore the molecular mechanism of microbial resistance and also examine their future applications in biotechnology and drug development. The study aimed at determining trends in antimicrobial resistance on a gene level and explaining the trends in biological terms of resistance mechanisms. The methodology is empirical because it makes use of structured genomic and resistance related data to examine the relationship between the determinants of resistance, resistance classes and genomic features. The research project will seek to produce a systematic data organization and interpretation to create a mechanism-based knowledge of antimicrobial resistance.

2.2 Data Source and Sample

The information used in the current work was obtained based on a curated antimicrobial resistance dataset of 50 microbial isolates (majority of Escherichia coli) (Kulkarni, 2025). All observations are single isolates, and include data on antimicrobial resistance genes, indicators of resistance classes, and genomic features (genome length and GC content).

The dataset consists of 112 variables, which are grouped as: gene-level resistance features, resistance-class indicators and supporting genomic variables. No observations were discarded during the analysis since all the observations offered a full reflection of resistance profiles and related biological features in the data.

2.3 Variables and Measures

The research used the determinants of antimicrobial resistance at the level of genes, and resistance-class indicators as the primary variables. The variables at the gene level were the genes that dealt with specific resistance such as: β-lactamase genes, aminoglycoside-modifying enzymes genes, tetracycline resistance genes and other antimicrobial

resistance genes. The Resistance-class variables represented the more general classes of antibiotics like aminoglycosides, carbapenems, cephalosporins, fluoroquinolones, sulfonamides, and tetracyclines hence giving a general picture of the resistance of the main drug groups.
To interpret, the resistance genes were categorized to major molecular mechanism categories that are enzymatic degradation, efflux-mediated resistance, target modification or protection, and membrane-associated resistance. Furthermore, biological context was provided with the help of genomic variables (genome length, GC content) whereas summary measures (total resistance genes, total resistance classes) were regarded as indicators of the burden of resistance.

2.4 Data Processing and Preparation

The dataset was analyzed beforehand to ascertain that it was structurally consistent and reliable. There were duplicate entries and inconsistencies that were also verified and no significant data quality problems were detected. The analysis did not focus on variables that have limited analytical value, particularly, incomplete metadata fields.
Derived summary variables were considered individually as opposed to primary gene and resistance-class features in order to prevent repetition in interpretation. Moreover, the resistance genes have been clustered into biologically significant molecular mechanism clusters based on the known functional activities in antimicrobial resistance, including enzymatic degradation, efflux-mediated resistance, target modification, and membrane-associated resistance.
Genomic variables, such as genome length and GC content were also checked continuously, to ensure consistency in biological interpretation. These preparatory measures made sure that this dataset was fit to be analyzed systematically on the determinants of resistance, resistance patterns and its general mechanistic implications to the biotechnology and drug development.

2.5 Data Analysis Technique

Data analysis was carried out in phases so as to get an overall picture of antimicrobial resistance trends. To summarize the distribution of the genomic variables, resistance genes and classes of resistance among the microbial isolates, first, descriptive statistical analysis was carried out. This has given a summary of the resistance determinants prevalence and variability.
Following this, mechanism based analysis has been conducted by clustering the resistance genes into their respective molecular resistance groups e.g. enzymatic degradation, efflux-mediated resistance, target modification and membrane-associated resistance. This aided in the determination of the prevailing biological pathways that were responsible in resistance expression.
Additional analysis was done to investigate patterns of co-occurrence of resistance genes and resistance classes in order to determine the most common combinations of resistance and potential combinations of multidrug resistance.
Lastly, the identified resistance mechanisms were put into the context of biotechnology and drug development through the identification of the resistance determinants in terms of class of antibiotics impacted and the discussion of their applicability to therapeutic challenge, inhibitor design and alternative possible treatment options.

3.1 Descriptive Analysis of Genomic and Resistance Variables

To summarize the key genomic and resistance related variables, descriptive statistical analysis was conducted. The isolates were characterized by low genome length and GC content variation, but with a high antimicrobial resistance load across the board. The mean count of the number of resistance genes and classes per isolate as shown in Table 1 demonstrates a high multidrug-resistant background.

Table 1: Descriptive Statistics of Selected Variables

Variable	Mean	Std. Dev	Min	Max
Genome Length (bp)	5,131,428	180,949	4,688,502	5,516,786
GC Content (%)	50.72	0.08	50.52	50.89
Total AMR Genes	45.92	2.58	43	51
Total Resistance Classes	23.18	0.60	21	25
Efflux-Mediated Genes	30.70	1.65	27	33
Enzymatic Degradation Genes	2.62	0.59	2	4

3.2 Distribution of Resistance Determinants

The frequencies of resistance determinants were tested to determine their relative frequencies. Table 2 indicates that a number of genes were very common in the isolates particularly the transport- and stress-associated determinants. Conversely, other resistance genes obtained were less frequent, which implies resistance diversity among microbial isolates. Figure 1 demonstrates that the frequency distribution of the antimicrobial resistance genes illustrates that there are some determinants that are very common among microbial isolates and others that are less common indicating variability in resistance.

Table 2: Distribution of Major Resistance Determinants

Resistance Determinant	Frequency	Percentage (%)
mdtM	49	98.0
eptA	49	98.0
gadX	49	98.0
acrF	49	98.0
mdfA	49	98.0
emrE	45	90.0
Ugd	42	84.0
ampC1 beta-lactamase	23	46.0
mphB	23	46.0
APH(3")-Ib	10	20.0
APH(6)-Id	10	20.0
sul2	10	20.0



Figure 1: Distribution of Antimicrobial Resistance Genes

3.3 Relationship Between Resistance Mechanism Categories

Mechanism-based analysis was conducted to compare the big categories of molecular resistance. The efflux-mediated resistance was most common as it was shown in Table 3 with enzymatic degradation, membrane-associated resistance, and target modification coming second. This trend indicates that the transport related systems and enzymes that inactivate drugs were the primary cause of microbial resistance. Figure 2 demonstrates that the most prevalent molecular mechanism, followed by enzymatic degradation, membrane-associated resistance, and target modification/protection, was efflux-mediated resistance.

Table 3: Distribution of Major Resistance Mechanism Categories

Mechanism Category	Mean	Std. Dev	Min	Max
Efflux-Mediated Resistance	30.70	1.65	27	33
Enzymatic Degradation	2.62	0.59	2	4
Membrane-Associated Resistance	1.84	0.51	1	3
Target Modification/Protection	1.76	0.83	1	5



Figure 2: Comparative Distribution of Resistance Mechanism Categories

3.4 Co-occurrence Patterns of Resistance Genes

Co-occurrence analysis was conducted to find out multidrug resistance combinations. Various resistance genes were often found in the same isolates as reported in Table 4. The highest co-occurrence was observed between ampC1 beta-lactamase and mphB, and combinations between APH genes and sul2, which evidence resistance expression.

Table 4: Major Co-occurring Resistance Gene Pairs

Gene Pair	Co-occurrence Frequency
ampC1 beta-lactamase + mphB	23
APH(3")-Ib + APH(6)-Id	10
APH(3")-Ib + sul2	10
APH(6)-Id + sul2	10
APH(3")-Ib + tet(A)	9
APH(6)-Id + tet(A)	9
mphB + sul2	9
ampC1 beta-lactamase + sul2	9

3.5Resistance Mechanisms and Implications for Drug Development

The resistance mechanisms identified were put into perspective concerning impacted antibiotic classes and treatment plans. Table 5 demonstrates that efflux systems were associated with a broad-spectrum resistance, and the beta-lactams were primarily degraded by enzymes. These results are an indication of the efflux inhibitors, enzyme inhibitors and combination therapies in the future development of drugs.

Table 5: Resistance Mechanisms and Therapeutic Implications

Resistance Mechanism	Major Affected Drug Class	Potential Therapeutic Strategy
Efflux-Mediated Resistance	Multiple antibiotic classes	Efflux pump inhibitors
Enzymatic Degradation	Beta-lactams	Beta-lactamase/enzyme inhibitors
Target Modification/Protection	Fluoroquinolones and others	Drug modification and alternative compounds
Membrane-Associated Resistance	Broad-spectrum antibiotics	Combination therapy and permeability-targeted strategies

4. DISCUSSION

The problem of antimicrobial resistance has evolved to be a more complex biological and a population health problem, with microorganisms currently having a variety of mechanisms to survive when exposed to antimicrobial agents. The results of this analysis indicate an overall high resistance burden among the microbial isolates and that there are high frequencies of resistance genes and classes of resistance found in the dataset. This trend is indicative of the larger issue of concern globally that resistance has ceased to be a solitary issue of drug-pathogen interaction but rather a multidimensional and global threat to the success of treatment, the health care system, and the overall success of infection control.

One of the key findings of the analysis is that most of the resistance mechanisms are efflux-mediated. Efflux systems have been reported to decrease intracellular concentrations of antimicrobial agents and this is due to the active transport of drugs out of the microbial cell. Their high frequency in the dataset implies that one of the most significant adaptive measures of resistant microorganisms is the transport-associated resistance. This observation is in line with previous molecular literature, which has found efflux pumps as key determinants of multidrug resistance, since they have the potential to co-target a wide variety of antibiotic classes concomitantly (Blair et al., 2015). The deep coverage of efflux-related determinants thus shows that not only isolated gene events but very adaptable and efficient physiological defense systems are driving the resistance.

Another significant resistance mechanism that was identified in the analysis is enzymatic degradation. Beta-lactamases are drug-inactivating enzymes that can counter antibiotics before the drugs can reach their target sites hence rendering the treatment ineffective. The proportion of enzyme degradation was less than that of efflux mediated resistance, but its effect is very significant due to its direct effect on the important groups of antibiotics used in clinical settings. The most recent literature has reiterated that even in the new treatment options, the resistance by enzyme-mediated inactivation remains a significant factor, particularly when it is coupled with other molecular cascades that promote survival of microbes (Nass & Zaher, 2025). This concerted effort makes treatment more challenging and leads to the recurrence of resistant populations.

The other significant observation is that multiple resistance determinants were observed to be reproducibly co-occurring in the same isolates. The clustering of the resistance genes identified indicates that microbial resistance is structured in well-coordinated patterns and not as a single-gene occurrence. These multidrug resistance patterns are especially worrisome since they decrease the efficacy of conventional monotherapy and make the choice of treatment more complicated. The same issues have been reported in the hospitalized population of patients, where antimicrobial-resistant infections were linked to more adverse clinical outcomes, increased hospitalization, and increased difficulty in management (Wolford et al., 2025). The fact that we do have co-occurring resistance genes in the dataset thus supports the significance of considering resistance architecture at the systems level.

The large number of resistance classes in the isolates also confirms the determination that the population of the microbe in question is of broad-spectrum resistance. The majority of isolates belonged to more than one type of antibiotic resistance, which shows that the resistance in this case is not limited to a small therapeutic index. This trend is in line with the evidence of global surveillance that indicates growing resistance among the major antibiotic groups and growing concern about the multidrug-resistant bacterial infections all over the world (World Health Organization, 2022) . The results of such studies underscore the increasing weaknesses of standard treatment methods and the imperative to develop more specific and mechanism-conscious treatment methods.

The mechanism-based organization of resistance determinants has a biotechnology perspective that can be used to offer more biological explanation. By grouping the resistance genes into categories, including efflux-mediated resistance, enzymatic degradation, target modification and membrane-associated resistance, it is now possible to not only know which genes are available, but also learn how they interact with each other to assist microbial survival. This is useful in practice in resistance surveillance, molecular diagnostics and genomic surveillance system (Nass & Zaher, 2025). Wide international evaluations of antimicrobial resistance have additionally highlighted the significance of incorporating molecular evidence to surveillance and response systems to enhance the ability to detect and respond swiftly.

The consequences of drug development are also crucial. The dominance of efflux systems and enzymatic degradation mechanisms implies that the therapeutic approaches of the future cannot be limited to finding new antibiotics, but the mechanisms of overcoming the molecular pathways which lower the effectiveness of drugs as well must be addressed. Efflux pump inhibitors, beta-lactamase inhibitors, combination therapy, alternative antimicrobial compounds are some of the approaches that can offer more sustainable responses to resistant infections. Recent studies are starting to point towards the conclusion that effective antimicrobial development should no longer be based on traditional antibiotic design, but that a combination of mechanism-based approaches that can reduce or overcome the most common resistance mechanisms should be developed.

5. CONCLUSION

Antimicrobial resistance is a dynamic and adaptive process of biology that goes beyond the direct drug-pathogen interactions to intricate web of molecular responses that guarantee the survival of microbes. The preponderance of efflux-mediated resistance and the regularity of enzymatic degradation processes in this research emphasizes the dependence of microorganisms on broad-spectrum and narrow-focus resistance mechanisms to sustain resistance to antimicrobial pressure. This architecture of layered resistance recommends that any future attempts to counter AMR should go beyond individual-target strategies and instead take into account the combination of multiple resistance mechanisms. A significant lesson of this work is that resistance determinants are more linked since the same isolates have multiple genes co-occurring. This implies that the resistance is not simply additive, but synergistic and that mechanisms acting together increase the overall resistance to antimicrobial agents. These trends highlight the importance of combined treatment approaches that take into account the overall resistance profile and not a single mechanism in isolation. A direction to be pursued in enhancing treatment efficacy is to target key resistance mechanisms like efflux systems and drug-inactivating enzymes. Also, genomic discoveries can be incorporated into

the creation of drugs and monitoring of resistance, which can help to implement more targeted and dynamic therapeutic interventions. Finally, to solve the problem of antimicrobial resistance, there is a need to move to multidisciplinary methods that involve molecular biology, biotechnology, and pharmacological innovation. Such coordinated efforts can only lead to sustainable and effective solutions to the increasing AMR challenge.

REFERENCES

1. Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015). Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology, 13(1), 42–51. https://doi.org/10.1038/nrmicro3380
2. Christaki, E., Marcou, M., & Tofarides, A. (2020). Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence. Journal of Molecular Evolution, 88(1), 26–40. https://doi.org/10.1007/s00239-019-09914-3
3. Hernández-Navarro, L., Asker, M., & Mobilia, M. (2024). Eco-evolutionary dynamics of cooperative antimicrobial resistance in a population of fluctuating volume and size. Journal of Physics A: Mathematical and Theoretical, 57(26), 265003. https://doi.org/10.1088/1751-8121/ad4ad6
4. Ho, C. S., Wong, C. T. H., Aung, T. T., Lakshminarayanan, R., Mehta, J. S., Rauz, S., McNally, A., Kintses, B., Peacock, S. J., Fuente-Nunez, C. de la, Hancock, R. E. W., & Ting, D. S. J. (2025). Antimicrobial resistance: A concise update. The Lancet Microbe, 6(1). https://doi.org/10.1016/j.lanmic.2024.07.010
5. Irfan, M., Almotiri, A., & AlZeyadi, Z. A. (2022). Antimicrobial Resistance and Its Drivers—A Review. Antibiotics, 11(10), 1362. https://doi.org/10.3390/antibiotics11101362
6. Konaklieva, M. I. (2019). Addressing Antimicrobial Resistance through New Medicinal and Synthetic Chemistry Strategies. SLAS DISCOVERY: Advancing the Science of Drug Discovery, 24(4), 419–439.
7. https://doi.org/10.1177/2472555218812657
8. Kulkarni, V. (2025). Antimicrobial Resistance Dataset.
https://www.kaggle.com/datasets/vihaankulkarni/antimicrobial-resistance-dataset
9. Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Aguilar, G. R., Mestrovic, T., Smith, G., Han, C., Hsu, R. L., Chalek, J., Araki, D. T., Chung, E., Raggi, C., Hayoon, A. G., Weaver, N. D., Lindstedt, P. A., Smith, A. E., … Murray, C. J. L. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: A systematic analysis with forecasts to 2050. The Lancet, 404(10459), 1199–1226.
10. https://doi.org/10.1016/S0140-6736(24)01867-1
11. Nass, N. M., & Zaher, K. A. (2025). Beyond the Resistome: Molecular Insights, Emerging Therapies, and Environmental Drivers of Antibiotic Resistance. Antibiotics, 14(10), 995.
12. https://doi.org/10.3390/antibiotics14100995
13. Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024). An Overview of the Recent Advances in Antimicrobial Resistance. Microorganisms, 12(9), 1920. https://doi.org/10.3390/microorganisms12091920
14. Sartori, M., Toppo, S., & Lavezzo, E. (2026). Molecular resistance mechanisms to newly approved antibiotics (2017–2025) in WHO priority pathogens. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1719798
15. Schardong, F., Struchiner, C. J., & Carvalho, L. M. (2026). Mapping the landscape of mathematical models for antimicrobial resistance: A scoping review (arXiv:2601.02308). arXiv. https://doi.org/10.48550/arXiv.2601.02308
16. Solanki, S., & Kumar Das, H. (2024). Antimicrobial resistance: Molecular drivers and underlying mechanisms. Journal of Medicine, Surgery, and Public Health, 3, 100122. https://doi.org/10.1016/j.glmedi.2024.100122
17. Wolford, H., McCarthy, N. L., Baggs, J., Hatfield, K. M., Maillis, A., Olubajo, B., Bishop, J., Ferretti, M., Craig, M. R., Magill, S. S., McDonald, L. C., Sievert, D. M., Walters, M. S., Jernigan, J. A., Lutgring, J. D., & Reddy, S. C. (2025). Antimicrobial-Resistant Infections in Hospitalized Patients.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831512
18. World Health Organization. (2022). Global antimicrobial resistance and use surveillance system (GLASS) report 2022. World Health Organization.